Mitsubishi UFJ Asset Management Co. Ltd. Increases Stock Holdings in InMode Ltd. (NASDAQ:INMD)

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of InMode Ltd. (NASDAQ:INMDFree Report) by 12.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 378,102 shares of the healthcare company’s stock after buying an additional 42,440 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.46% of InMode worth $7,940,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Principal Securities Inc. acquired a new position in InMode during the fourth quarter worth about $32,000. Sunbelt Securities Inc. acquired a new position in shares of InMode during the 3rd quarter worth approximately $47,000. CWM LLC lifted its stake in InMode by 38.3% in the 4th quarter. CWM LLC now owns 2,454 shares of the healthcare company’s stock valued at $55,000 after buying an additional 680 shares in the last quarter. NBC Securities Inc. acquired a new stake in InMode during the 3rd quarter valued at $79,000. Finally, Covestor Ltd grew its holdings in InMode by 83.2% during the 3rd quarter. Covestor Ltd now owns 3,291 shares of the healthcare company’s stock valued at $100,000 after buying an additional 1,495 shares during the last quarter. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

InMode Trading Down 1.0 %

Shares of NASDAQ:INMD opened at $18.46 on Friday. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of 8.75 and a beta of 2.20. The stock’s 50-day moving average price is $19.14 and its two-hundred day moving average price is $21.26. InMode Ltd. has a 12-month low of $16.72 and a 12-month high of $48.25.

Analysts Set New Price Targets

Several brokerages have recently issued reports on INMD. Needham & Company LLC restated a “hold” rating on shares of InMode in a research report on Friday, May 3rd. Barclays reduced their target price on shares of InMode from $34.00 to $33.00 and set an “overweight” rating on the stock in a report on Friday, April 12th. Finally, UBS Group lifted their price target on shares of InMode from $24.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, February 14th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $32.80.

Read Our Latest Stock Analysis on InMode

InMode Profile

(Free Report)

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.

Featured Stories

Want to see what other hedge funds are holding INMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InMode Ltd. (NASDAQ:INMDFree Report).

Institutional Ownership by Quarter for InMode (NASDAQ:INMD)

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.